NIAID Director: HIV remission free of antiretroviral therapy is a feasible goal

July 25, 2018, NIH/National Institute of Allergy and Infectious Diseases
The NIAID Director Anthony S. Fauci, M.D. Credit: NIAID

Long-lasting control of HIV infection without antiretroviral therapy (ART) is a feasible goal that deserves vigorous pursuit, Anthony S. Fauci, M.D., will assert during a lecture on Wednesday, July 25 at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam. Dr. Fauci directs the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. His lecture is titled, "Durable Control of HIV Infection in the Absence of Antiretroviral Therapy: Opportunities and Challenges."

An HIV cure in the classic sense requires the elimination of all virus-carrying cells, known collectively as the HIV reservoir. These cells, which have DNA encoding HIV proteins, have entered a resting state such that they do not produce any parts of the virus. HIV reservoir cells can survive for years, even for life, while remaining invisible to the immune system. Although research toward a classic cure is under way, Dr. Fauci notes that additional scientific breakthroughs will be needed to achieve that goal.

An alternative goal to a classic cure is sustained, ART-free remission, according to Dr. Fauci. This objective would not involve eradicating the HIV reservoir. Rather, it would allow a person living with HIV to keep latent virus suppressed without daily medication. Today, people living with HIV typically must take ART—usually a daily regimen of three or more antiretroviral drugs—to stay healthy and prevent transmitting the virus to others.

Scientists are taking two broad approaches toward ART-free remission, Dr. Fauci will explain. One approach consists of intermittent or continual non-ART interventions, while the other involves stimulating the immune system to independently exert long-lasting control over HIV.

Promising intermittent or continual interventions for long-lasting, ART-free remission include broadly neutralizing HIV (bNAbs), according to Dr. Fauci. These powerful antibodies can stop nearly all strains of HIV from infecting cells in the laboratory. Studies are underway in animals and people to determine whether periodic infusions or injections of bNAbs can prevent HIV acquisition as well as suppress the virus in people living with HIV. Dr. Fauci will describe how scientists are developing bNAbs with improved attributes, including greater potency and longer duration in the body, and are testing treatment with combinations of two or three bNAbs in a manner akin to combination . He will express cautious optimism that combination bNAb therapy will succeed.

Scientists also are testing whether delivering either bNAbs against the virus or antibodies against parts of the immune system can produce ART-free remission by inducing long-lasting, immune-mediated control of the virus without further intervention, Dr. Fauci will explain. A study led by scientists at NIAID and Rockefeller University showed that giving infusions of two different bNAbs to monkeys infected with a simian form of HIV enabled the immune systems of some of the animals to control the virus long after the antibodies were gone.

Another study led by scientists at Emory University in collaboration with Dr. Fauci's lab involved antibodies that bind to a host immune cellular receptor called alpha-4 beta-7. Dr. Fauci will describe how giving short-term ART and infusions of the anti-alpha-4 beta-7 antibody to monkeys infected with a simian form of HIV led to prolonged control of the virus and replenishment of immune cells after all treatment stopped. He will note that an NIH study that tried to replicate this outcome did not achieve consistent results.

Finally, Dr. Fauci will report preliminary results of a small, early-phase clinical trial in which people living with HIV that was well controlled with ART received infusions of vedolizumab, an anti-alpha-4-beta-7 antibody that is FDA-approved for ulcerative colitis and Crohn's disease. These volunteers received both ART and vedolizumab at the beginning of the study, paused ART while continuing to receive the antibody, and finally stopped all treatment. He will describe how the regimen was safe and well tolerated but did not generate lasting control of the . He also will posit potential explanations for the differences between the alpha-4 beta-7 studies in monkeys and people.

Dr. Fauci's lecture will be live-streamed on the AIDS 2018 website.

Explore further: Research helps explain how antibody treatment led to lasting HIV-like virus remission

Related Stories

Research helps explain how antibody treatment led to lasting HIV-like virus remission

February 15, 2017
Scientists at the National Institutes of Health have found that the presence of the protein alpha-4 beta-7 integrin on the surface of HIV and its monkey equivalent—simian immunodeficiency virus, or SIV—may help explain ...

Broadly neutralizing antibody treatment may target viral reservoir in monkeys

March 5, 2018
After receiving a course of antiretroviral therapy for their HIV-like infection, approximately half of a group of monkeys infused with a broadly neutralizing antibody to HIV combined with an immune stimulatory compound suppressed ...

Genetically altered broadly neutralizing antibodies protect monkeys from HIV-like virus

April 16, 2018
Two genetically modified broadly neutralizing antibodies (bNAbs) protected rhesus macaques from an HIV-like virus, report scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National ...

Study links gut-homing protein levels with HIV infection risk, disease progression

January 24, 2018
For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes. ...

Antibodies show effectiveness for HIV prevention and promise for treatment and cure

January 17, 2018
The ability of HIV to mutate has been a major challenge to vaccine development. As the body produces antibodies to target the outer HIV envelope protein, this protein changes, thwarting the circulating antibodies' ability ...

HIV antibodies block infection by reservoir-derived virus in laboratory study

August 26, 2014
A laboratory study led by scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), lends further weight to the potential effectiveness of passive immunotherapy ...

Recommended for you

Roadmap reveals shortcut to recreate key HIV antibody for vaccines

December 11, 2018
HIV evades the body's immune defenses through a multitude of mutations, and antibodies produced by the host's immune system to fight HIV also follow convoluted evolutionary pathways that have been challenging to track.

Eliminating the latent reservoir of HIV

December 7, 2018
A new study suggests that a genetic switch that causes latent HIV inside cells to begin to replicate can be manipulated to completely eradicate the virus from the human body. Cells harboring latent HIV are "invisible" to ...

New research highlights why HIV-infected patients suffer higher rates of cancer

December 5, 2018
AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer—among the leading causes of death ...

Focus on resistance to HIV offers insight into how to fight the virus

November 30, 2018
Of the 40 million people around the world infected with HIV, less than one per cent have immune systems strong enough to suppress the virus for extended periods of time. These special immune systems are known as "elite controllers." ...

Patients with rare natural ability to suppress HIV shed light on potential functional cure

November 27, 2018
Researchers at Johns Hopkins have identified two patients with HIV whose immune cells behave differently than others with the virus and actually appear to help control viral load even years after infection. Moreover, both ...

Scientists unveil promising new HIV vaccine strategy

November 26, 2018
A new candidate HIV vaccine from Scripps Research surmounts technical hurdles that stymied previous vaccine efforts, and stimulates a powerful anti-HIV antibody response in animal tests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.